ProPhase Labs shareholders approve share increase to 1B and equity plans

ProPhase Labs, Inc.

Shareholders approved increase in authorized common shares from 50M to 1B at Sept 9 special meeting.
Approved amendments to 2022 equity plan and 2025 equity plan, enabling executive participation.
Warrants to CEO Ted Karkus and an investor for 500k shares each now fully exercisable.
Company can now reserve 400% of shares for conversion of July 2025 20% OID notes and warrants.
Bylaw amendment to update principal office address approved.

item 1.01 item 5.02 item 5.03 item 5.07 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

ProPhase Labs, Inc.: Updated principal office address to RXR Plaza, Uniondale, New York (effective 2025-09-09).

Change: bylaw amendment
Effective: 2025-09-09

Exact text from the filing

stockholders approved an amendment to the Company’s Amended and Restated Bylaws to update the Company’s principal office address to RXR Plaza, Uniondale, New York (Proposal 6).

View on SEC.gov

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

ProPhase Labs, Inc.: Increased number of authorized shares of common stock from 50,000,000 to 1,000,000,000 (effective 2025-09-09).

Change: charter amendment
Effective: 2025-09-09

Exact text from the filing

stockholders also approved Certificate of Amendment to its Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 50,000,000 to 1,000,000,000.

View on SEC.gov

84 governance changes filed in the last 30 days. Browse all governance changes →

ProPhase Labs, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-25-013415

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.